Post breakout from the rounding bottom pattern in August 2022, Jyothy Labs prices retested the neckline and have shown a bounce on upside pointing towards beginning of the trend on the upside.
Apart from the drug used as part of the treatment for a type of blood cancer, other medicines going off-patent will boost the prospects of companies like Dr Reddy’s and Cipla, the healthcare analyst at Sanford Bernstein said.
Sharekhan is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1225 in its research report dated September 09, 2022.
Cipla on the daily chart has formed a strong rounding base formation and is on the verge of a breakout. The F&O data, too, suggest the building of fresh long positions with the rise in price and rise in open interest.
According to external data that Cipla provided, Revlimid (Lenalidomide) capsules had US sales of approximately $2.58 billion for the 12-month period ending June 2022
The company has received the final approval from the US Food and Drug Administration (USFDA) for the product in strengths of 5 mg, 10 mg, 15 mg and 25 mg, Cipla said in a regulatory filing.
European markets closed lower as traders grappled with fears of higher interest rates and a looming economic downturn. India’s GDP growth surged 13.5% in April-June period driven by a favourable base effect and ongoing economic revival. We decode the numbers on the show.
These are the stocks that will possibly be in the spotlight during trading hours on September 01, Thursday. We explain the reasons why these stocks are buzzing before the Opening Bell and the factors that could come into play in trade. Check out this curated list of buzzing stocks from the Moneycontrol markets team and why they are in the news.
In an exclusive interview with CNBC-TV18, Umang Vohra said that the pharma major is looking at China, Brazil, South Africa, and Australia as key markets, apart from India
Motilal Oswal recommended Neutral rating on Cipla with a target price of Rs 950 in its research report dated August 18, 2022.
The new appointment will relieve Dinesh Jain from the additional responsibility of interim Chief Financial Officer.
For the week, 17,500–17,650 remains a sturdy wall and until it is surpassed convincingly, tentativeness at higher levels will persist
On the weekly chart of Alkyl Amines, the prices have shown a bounce on the upside. In the prior week, prices gave a breakout from the Falling Wedge pattern which is a bullish reversal pattern, said Vidnyan Sawant of GEPL Capital
Arihant Capital recommended hold rating on Cipla with a target price of Rs 1080 in its research report dated August 01, 2022.
Prabhudas Lilladher is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1110 in its research report dated August 01, 2022.
On the recommendation of the nomination and remuneration committee and subject to the approval of the shareholders at the ensuing annual general meeting, the company’s board has appointed Vaidya.
Cipla is building its Peptide pipeline with the recently launched Lanreotide injection, which has been well received
ICICI Direct is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1135 in its research report dated July 30, 2022.
Sharekhan is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1150 in its research report dated July 29, 2022.
On last Friday, Cipla finally managed to traverse through a neckline resistance of ‘Inverse Head and Shoulder’ pattern around Rs 960 on a closing basis. In addition, the positive placement of ‘RSI-Smoothened’ is likely to provide the much-needed impetus for the next leg of the rally
This acquisition is in line with Cipla's strategic imperative to augment the Company's wellness portfolio for bringing about a shift from an illness to a wellness mindset.
Net Sales are expected to decrease by 1.2 percent Y-o-Y (up 3.4 percent Q-o-Q) to Rs 5,439.3 crore, according to ICICI Direct.
Net Sales are expected to increase by 2.9 percent Y-o-Y (up 7.7 percent Q-o-Q) to Rs 5,665.5 crore, according to Prabhudas Lilladher.